Pay in 4 interest-free payments of $6.95 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
Noncommunicable Diseases Obesity Prevention Guidelines Noncommunicable Diseases and Mental Health (NMH)
The STEP clinical trials have demonstrated average weight reductions of 10-15% of body weight over 68 weeks when combined with lifestyle modifications
The most common side effects Nausea and a feeling of early satiety Vomiting Diarrhoea or constipation Abdominal pain/heavy feeling, bloating, acid reflux Loss of appetite (sometimes excessive) Contraindications and risks to be aware of Possible problems with the gallbladder or bile ducts in some people (particularly with rapid weight loss) Caution is advised in people who have had pancreatitis or who have symptoms suggestive of it (always to be assessed by a doctor) Risk of hypoglycaemia when used in combination with insulin or sulphonylureas (a dose adjustment may be necessary) Interactions with oral medicines: delayed gastric emptying may affect the absorption of certain medicines Thyroid-related issues: the PRAC/EMA concluded that the available evidence does not support a causal link between the GLP-1 receptor agonists assessed and thyroid cancer, although monitoring and appropriate use remain important Frequently asked questions What exactly is the GLP-1 hormone
Tip: Please fill out the form if you or a friend would like more information on continuous glucose monitors
Metabolism of zearalenone in farm animals
